We have detected you are coming from a location outside of Germany.
Wir haben festgestellt, dass Sie von einem Standort außerhalb Deutschlands auf diese Seite gelangt sind.

Please select your preferred language:
Bitte wählen Sie eine der folgenden Sprachoptionen:

Go back

DxOme® - Next Generation Sequencing

The DxOme® is a comprehensive NGS approach that enriches over 1500 genes. This is especially true for medical cases in which a gene panel diagnostic, which is primarily to be preferred and is based on the main clinical symptoms, has not led to a diagnosis. The DxOme® is also useful if the presence of a complex phenotype prevents gene selection in the sense of a phenotype-based gene panel.

In addition, DxOme® offers key advantages over Clinical Exome Sequencing (CES) and Whole Exome Sequencing (WES) in terms of:

  • the focus on genes that are clinically relevant (clear association with the disease),
  • the possibility of data evaluation according to differential diagnostic aspects (HPO-Term based),
  • a high to very high quality of analysis (high technical coverage of the target regions),
  • the analysis of relevant non-coding variants (coverage of relevant intronic areas),
  • deletions / duplications, and
  • a short analysis time in the prenatal and critical postnatal situations (10 working days).

The DxOme® contains over 1500 genes in the following areas:

  • Eye Diseases
  • Vascular and Connective Tissue Diseases
  • Heart Diseases
  • Brain Malformations / Neuronal Migration Disorders
  • Hepatic and Pancreatic Diseases
  • Pulmonary Diseases
  • Nephrology, Endocrinology, and Electrolytes
  • Neurogenetic Disorders
  • Neuromuscular Disorders
  • Mental Retardation and Dysmorphology
  • Metabolic Diseases

The DxOme® is  now available as part of our new diagnostic process. You can read more about the DxOme® test options under Gene Panel Sequencing

Questions about MGZ’s DxOme? Send an email to inquiry@mgz-muenchen.com.